Revisiting Barriers to Clinical Trials Accrual
A partir d'une revue systématique de la littérature publiée entre 2000 et 2020 (35 études), cette méta-analyse évalue aux Etats-Unis la proportion de patients atteints d'un cancer ayant accepté de participer à un essai clinique
Properly conducted clinical trials provide high-quality evidence for a spectrum of outcomes relevant to patients, care providers, policy makers and funders of health care services. While such trials often have high internal validity, their external validity, or generalizability, depends on how representative the patients enrolled in a given trial are for the general target population.Only about 5% to 8% of cancer patients participate in clinical trials, and studies conducted in the United Statesindicate that patients who are enrolled in trials are,on average,younger, better educated, less racially diverse, and with fewer comorbid conditionscompared to typical patients with the condition of interest. These findings raiseconcern as to the validity of the trial-estimated treatment benefits and risks when applied in the “real world”.
Journal of the National Cancer Institute , éditorial en libre accès, 2019